BioSpace News Archive

GE Healthcare announced today the FDA pre-market approval (PMA) for its End-tidal (Et) Control software for general anesthesia delivery on its Aisys CS2 Anesthesia Delivery System.

Interrad Medical, a privately held medical device company, announces its SecurAcath device has received an Innovative Technology contract from Vizient, Inc., the largest member-driven health care performance improvement company in the country.

ATCC, the world’s premier biological materials management and standards organization, announced that it has entered into an agreement with QIAGEN, a recognized leader in bioinformatics solutions, to provide them with sequencing data from its collection of cell lines, and animal and human biological materials.

Pear Therapeutics, Inc. today announced a program to offer patients seeking treatment for substance use disorder (SUD) or opioid use disorder (OUD) access to a telehealth provider through its “find a provider tool”, along with in-person care options.

Orum Therapeutics today announced the formation of its scientific advisory board (SAB).

Agilent Technologies Inc. (NYSE: A) announced today that it has become a member of the Advanced Mammalian Biomanufacturing Innovation Center (AMBIC).

eFFECTOR Therapeutics, Inc. today announced that its chief medical officer Premal Patel, M.D., Ph.D., has resigned to pursue a new opportunity. Robert Sikorski, M.D., Ph.D., who currently serves as a clinical advisor to the company, will take on an expanded role as senior clinical development advisor while the company conducts an executive search for a new chief medical officer.

Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, announced that members of Journey Medical’s management team will participate in the two-day Fortress Biotech Virtual R&D Summit taking place on Tuesday, April 5, 2022 and Wednesday, April 6, 2022.

Telix Pharmaceuticals Limited announces that its prostate cancer imaging agent, Illuccix®, also known as 68Ga-PSMA-11 injection, is now commercially available in the United States.

Acer Therapeutics Inc. today announced the U.S. Food and Drug Administration (FDA) has granted celiprolol Breakthrough Therapy designation (BTD) in the U.S. for the treatment of patients with COL3A1-positive vascular Ehlers-Danlos syndrome (vEDS).